This is not the most recent version of the article. View current version (9 JAN 2016)

Intervention Review

You have free access to this content

Interval debulking surgery for advanced epithelial ovarian cancer

  1. Siriwan Tangjitgamol1,*,
  2. Sumonmal Manusirivithaya2,
  3. Malinee Laopaiboon3,
  4. Pisake Lumbiganon4,
  5. Andrew Bryant5

Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Published Online: 30 APR 2013

Assessed as up-to-date: 5 MAR 2013

DOI: 10.1002/14651858.CD006014.pub6


How to Cite

Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P, Bryant A. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD006014. DOI: 10.1002/14651858.CD006014.pub6.

Author Information

  1. 1

    Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Department of Obstetrics and Gynaecology, Bangkok, Thailand

  2. 2

    Research Facilitation Divison, Faculty of Medicine Vajira Hospital, Khon Kaen, Thailand

  3. 3

    Khon Kaen University, Department of Biostatistics and Demography, Faculty of Public Health, Khon Kaen, Thailand

  4. 4

    Khon Kaen University, Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen, Thailand

  5. 5

    Newcastle University, Institute of Health & Society, Newcastle upon Tyne, UK

*Siriwan Tangjitgamol, Department of Obstetrics and Gynaecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, 681 Samsen Road, Dusit District, Bangkok, 10300, Thailand. siriwanonco@yahoo.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

This is not the most recent version of the article. View current version (09 JAN 2016)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Redman 1994 {published data only}
  • Redman CW, Warwick J, Luesley DM, Varma R, Lawton FG, Blackledge GR. Intervention debulking surgery in advanced epithelial ovarian cancer. British Journal of Obstetrics and Gynaecology 1994;101:142-6.
  • Varma R, Blackledge G, Redman C, Luesley D, Chan KK, Mould J. A randomised trial of intervention debulking surgery and the duration of cis-platinum combination chemotherapy in advanced epithelial ovarian cancer (EOC). Annals of Oncology. 1990; Vol. 1 (Suppl 9):4.
Rose 2004 {published data only}
  • Rose PG, Nerenston S, Brady MF, Clarke Pearson D, Olt G, Rubin SC, et al. Operative morbidity following primary and interval debulking surgery for advanced ovarian cancer. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 23:450.
  • Rose PG, Nerenstone S, Brady M, Clarke Pearson D, Olt G, Rubin SC, et al. A phase III randomised study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proceedings of the American Society of Clinical Oncology. 2002; Vol. 21 (Pt 1):201a.
  • Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. The New England Journal of Medicine 2004;351:2489-97.
Van der Burg 1995 {published data only}
  • Van der Burg ME, Coens C, Van Lent M, Kobierska A, Colombo N, Favalli G, et al. After ten years follow-up interval debulking surgery remains a significant prognostic factor for survival and progression free survival for advanced ovarian cancer: the EORTC Gynaecological Cancer Group study. International Journal of Gynecological Cancer. 2004; Vol. 14 (Suppl 1):3.
  • Van der Burg ME, Van Lent M, Kobierska A, Colombo N, Favalli G, Lacave AJ, et al. Intervention debulking surgery (IDS) does improve survival in advanced epithelial ovarian cancer (EOC); an EORTC gynecological cancer cooperative group (GCCG) study. Proceedings of the American Society of Clinical Oncology. 1993; Vol. 12:258.
  • Van der Burg ME, Van Lent M, Kobierska A, Colombo N, Favalli G, Lacave AJ, et al. Intervention debulking surgery (IDS) does increase survival in advanced epithelial ovarian cancer (OC) - an EORTC Gynecological Cancer Cooperative Group (GCCG) study. European Journal of Cancer. 1993; Vol. 29 (Suppl 6):S132.
  • Van der Burg MEL, Coens C, Van Lent M, Kobierska A, Colombo M, Favalli G, et al. The survival benefit of interval debulking surgery (IDS) in advanced ovarian cancer is maintained during ten years; the EORTC GCG 55865 study. International Journal of Gynecologic Cancer. 2005; Vol. 15 (supplement 2):79.
  • Van der Burg MEL, Van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the EORTC. The New England Journal of Medicine 1995;332(10):629-34.
  • Van der Burg MEL, Van Lent M, Buyse M, Kobierska A, Maggioni A, Favalli G, et al. The role of intervention debulking surgery in advanced epithelial ovarian cancer: An EORTC Gynecological Cancer Cooperative Group study. International Journal of Gynecological Cancer 1996;6 (5 Suppl 1):30-8.
  • Van der Burg MEL, Van Lent M, Kobierska A, Colombo N, Favalli G, Lacave AJ, et al. Secondary tumor debulking itself does not increase survival in advanced epithelial ovarian cancer (EOC); an EORTC Gynecological Cancer Cooperative (GCCG) study. International Journal of Gynecological Cancer. 1993; Vol. 3 (Suppl 1):52.
  • Van der Burg MEL, Van Lent M, Kobierska A, Pitelli MR, Favalli G, Lacave AJ, et al. After 6 years follow-up intervention debulking surgery remains an independent prognostic factor for survival in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study. International Journal of Gynecological Cancer. 1997; Vol. 7 (Suppl 2):28.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Angioli 2006 {published data only}
  • Angioli R, Palaia I, Zullo MA, Muzii L, Manci N, Calcagno M, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecologic Oncology 2006;100:455-61.
Chan 2003 {published data only}
  • Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecologic Oncology 2003;88:9-16.
Dutta 2005 {published data only}
  • Dutta T, Sharma H, Kumar L, Dinda AK, Kumar S, Bhatla N, et al. Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis. Cancer Chemotherapy and Pharmacology 2005;56(4):427-35.
Evdokimova 1982 {published data only}
  • Evdokimova NI, Grigorova TM. Comparative study of 2 combined treatment regimens in stage-III to -IV ovarian cancer. Voprosy onkologii 1982;28(7):28-34.
Fuso 2006 {published data only}
Giannopoulos 2006 {published data only}
  • Giannopoulos T, Butler-Manuel S, Taylor A, Ngeh N, Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. European Journal Gynaecologic Oncology 2006;27:25-8.
Ikeba 2004 {published data only}
  • Ikeba K, Okubo M, Takeda S, Kinoshita K, Maeda H. Five-year results of cyclic semi-high dose neoadjuvant chemotherapy supported by autologous peripheral blood stem-cell transplantation in patients with advanced ovarian cancer. International Journal Clinical Oncology 2004;9:113-9.
JCOG 2009 {published data only}
  • Onda T,  Kobayashi H,  Nakanishi T,  Hatae M,  Iwasaka T, Konishi I, et al. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecologic Oncology 2009;113(1):57-62.
Kuhn 2001 {published data only}
Kumar 2009 {published data only}
  • Janga D, Kumar L, Kumar S, Shukla NK, Thulkar S, Singh R. Neoadjuvant chemotherapy (CT) followed by debulking surgery vs upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma (EOC): a prospective, randomized study. Proceedings of the American Society of Clinical Oncology 2003. 2007; Vol. 22:487:Abstract 1957.
  • Kumar L, Hariprasad R, Kumar S, Bhatla N, Thulkar S, Vijayaraghavan M, et al. Neoadjuvant chemotherapy followed by interval debulking surgery versus upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma: a prospective randomized study - interim results. Proceeding of the ASCO Annual Meeting 2007, Part I. 2007; Vol. 28, issue 18 (Suppl):Abstract 5531.
  • Kumar L, Hariprasad R,   Kumar S, Bhatla N,  Thulkar S,  Shukla NK . Neo-adjuvant chemotherapy in advanced epithelial ovarian cancer (eoc): A prospective, randomized study. Indian Journal of Medical and Paediatric Oncology 2009;30(1):15. [: NCT00715286]
Lee 2006 {published data only}
Liu 2004 {published data only}
  • Liu EL, Mi RR. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma. Chinese Medical Journal 2004;117:1547-51.
Matulonis 2009 {published data only}
  • Matulonis UA,  Krag KJ,  Krasner CN,  Atkinson T,  Horowitz NS,   Lee H, et al. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecologic Oncology 2009;112(2):394-399.
Park-Simon 2006 {published data only}
  • Park-Simon T, Jänicke F, Ortmann O, Hilfrich J, Breitbach G, Höss C, et al. A randomized multicenter phase II study on neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian carcinomas (PRIMOVAR). Journal of Clinical Oncology: 2006 ASCO Annual meeting proceedings 2006;24(18S (June 20 Supplement)):Abstract 15025.
Polcher 2009 {published data only}
  • Polcher M,  Mahner S,  Ortmann O,  Hilfrich J,  Diedrich K,  Breitbach GP, et al. Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR). Oncology Reports 2009;22(3):605-613.
Recchia 2001 {published data only}
  • Recchia F, De Filippis S, Rosselli M, Saggio G, Carta G, Rea S. Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. European Journal of Gynaecologic Oncology 2001;22:287-91.
Solomon 1988 {published data only}
Tiersten 2009 {published data only}
  • Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR III, Markman M, et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelail ovarian, fallopian tube or primary peritoneal cancer: Soutwest Oncology Group Study S0009. Gynecologic Oncology 2009;112:444-9.
Vergote 2010 {published data only}
  • EORTC 55971. A randomized phase III study comparing upfront debulking surgery vs neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma. IGCS 12th Biennial Meeting. 2008.
  • Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine  2010;363(10):943-53.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Ansquer 2001
Bristow 2002
  • Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 2002;20:1248-59.
Bristow 2006
  • Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic Oncology 2006;103(3):1070-6.
Bristow 2007
  • Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecologic Oncology 2007;104(2):480-90.
Bucher 1997
  • Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91.
Cochrane Handbook
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Deeks 2001
  • Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition). BMJ Publication Group, London, 2001.
DerSimonian 1986
Elattar 2011
Elit 1995
  • Elit A, Carey M. The role of interval debulking surgery in advanced ovarian cancer: a meta-analysis. International Journal of Gynecological Cancer. 1995; Vol. 5 (Suppl 1):37 (abstract).
Fanfani 2003
  • Fanfani F, Ferrandina G, Corrado G, Fagotti A, Vito Zakut H, Mancuso S, et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 2003;65:316-22.
GLOBOCAN 2008
Griffiths 1975
  • Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Journal of the National Cancer Institute Monographs 1975;42:101-4.
Higgins 2003
Hoskin 1994
  • Hoskins WJ, McGuire WP, Brady MF, Homsley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology 1994;170:974-80.
Jacob 1991
Kayikçioglu 2001
  • Kayikçioglu F, Köse MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced ovarian carcinoma.. International Journal of Gynecological Cancer 2001;11(6):446-70.
Kehoe 1995
Lawton 1989
  • Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstetrics and Gynecology 1989;73:61-5.
Loizzi 2005
Mazzeo 2003
  • Mazzeo F, Berliere M, Kerger J, Squifflet J, Duck L, D'Hondt V, et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecologic Oncology 2003;90:163-9.
Morice 2003
  • Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. Journal of the American College of Surgeons 2003;197:955-63.
Morrison 2012
Parmar 1998
Schwartz 1999
Shibata 2003
Surwit 1996
Van der Burg 2003
  • Van der Burg ME, Vergote I, Gynecological Cancer Group of the EORTC. The role of interval debulking surgery in ovarian cancer. Current Oncology Reports 2003;5:473-81.
Van der Burg 2005
  • Van der Burg MEL, Coens C, Van Lent M, Kobierska A, Colombo M, Favalli G, et al. The survival benefit of interval debulking surgery (IDS) in advanced ovarian cancer is maintained during ten years; the EORTC GCG 55865 study. International Journal of Gynecologic Cancer. 2005; Vol. 15 (supplement 2):79.
Vergote 1998
  • Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, Van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecologic Oncology 1998;71:431-6.
Wenzel 2005
  • Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2005;23:5605-12.